Condition: Dental Diseases · Sponsor: University Hospital, Toulouse
The main objective of this study is to assess the prevalence of dental discoloration (dental dyschromia) in children who experienced high levels of bilirubin in their blood (hyperbilirubinemia) during their early years. The study will also examine risk factors associated with this condition, such as the duration and severity of hyperbilirubinemia, underlying diseases, and treatments received. The researchers hypothesize that the quality of life of individuals with dental dyschromia is lower than that of individuals without dyschromia. The results of this study will be used to discuss coverage for dental care with health insurance for children affected by this condition.
This description comes directly from the study's public registry record.
Nolwenn LABORDE, MD · 05 61 77 96 70 · laborde.n@chu-toulouse.fr
Romain LOPEZ, PharmD · lopez.ro@chu-toulouse.fr
Always discuss trial participation with your own doctor first.
| University Hospital Bordeaux | Bordeaux, France | Recruiting |
| University Hosptial Caen | Caen, France | Recruiting |
| University Hospital Lille | Lille, France | Recruiting |
| Hospices Civils de Lyon | Lyon, France | Recruiting |
| University Hospital Marseille | Marseille, France | Recruiting |
| Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, FHU Hépatinov | Paris, France | Recruiting |
| Assistance Publique-Hôpitaux de Paris, Hôpital Bretonneau, Paris | Paris, France | Recruiting |
| Assistance Publique-Hôpitaux de Paris, Hôpital Necker | Paris, France | Recruiting |
| University Hospital Rennes | Rennes, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06506734